Teng Yan, Tang Hui, Yu Yong, Fan Yibin, Tao Xiaohua, Xu Danfeng
Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China.
Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu, People's Republic of China.
J Asthma Allergy. 2023 Aug 1;16:789-792. doi: 10.2147/JAA.S422836. eCollection 2023.
There is limited literature on AD with a predominant involvement of nipple among the adult male group. SARS-CoV-2 infection might have been an exacerbating factor of AD by initiating the "cytokine storm". Conventional treatment suffers from a dilemma of poor efficacy and a high recurrence. The JAK inhibitors have been clinically applied to treat the AD with a good outcome.
We present a case of a 28-year-old male AD patient with a predominant nipple involvement successfully treated with JAK inhibitor abrocitinib, with no adverse affects.
The case shows a good clinical efficacy of JAK inhibitor abrocitinib in the treatment of AD with a predominant nipple involvement during the COVID-19 pandemic with a rapid and long-term symptomatic relief.
JAK inhibitor abrocitinib might become a promising agent for the treatment with AD with a predominant uncommon region like nipple that might be resistant to conventional therapies during the COVID-19 pandemic.
在成年男性群体中，以乳头为主受累的特应性皮炎相关文献有限。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染可能通过引发“细胞因子风暴”成为特应性皮炎的一个加重因素。传统治疗存在疗效不佳和高复发率的困境。Janus激酶（JAK）抑制剂已在临床上用于治疗特应性皮炎，效果良好。
我们报告一例28岁男性特应性皮炎患者，以乳头为主受累，使用JAK抑制剂阿布昔替尼成功治疗，无不良反应。
该病例显示JAK抑制剂阿布昔替尼在治疗新冠疫情期间以乳头为主受累的特应性皮炎方面具有良好的临床疗效，能迅速且长期缓解症状。
在新冠疫情期间，JAK抑制剂阿布昔替尼可能成为治疗乳头等对传统疗法可能耐药的不常见部位为主受累的特应性皮炎的一种有前景的药物。
